Search

Your search keyword '"Droitcourt, C."' showing total 369 results
Start Over Author "Droitcourt, C."
369 results on '"Droitcourt, C."'

1. Isotretinoin: Past, present and future. A French perspective

Author

Leducq, S., Poizeau, F., Chaby, G., Tannous, J., Ballanger-Desolneux, F., Baubion, E., Bertolotti, A., Cogrel, O., Droitcourt, C., Garnier, V., Gautier, S., Hefez, L., Hotz, C., Jonville-Béra, A.-P., Jouan, N., Mahé, A., Mahé, E., Martinho, G., Micallef, J., Puszkarek, T., Dupin, N., Ly, S., Beylot-Barry, M., Corgibet, F., Guillot, B., and Chosidow, O.

Published
2024
Full Text
View/download PDF

2. Isotrétinoïne : quelles actualités en dermatologie ? Conclusions du séminaire Centre de preuves en dermatologie et groupe DEFI de la SFD

Author

Leducq, S., Poizeau, F., Chaby, G., Tannous, J., Ballanger-Desolneux, F., Baubion, E., Bertolotti, A., Cogrel, O., Droitcourt, C., Garnier, V., Gautier, S., Hefez, L., Hotz, C., Jonville-Béra, A.-P., Jouan, N., Mahé, A., Mahé, E., Martinho, G., Micallef, J., Puszkarek, T., Dupin, N., Ly, S., Beylot-Barry, M., Corgibet, F., Guillot, B., and Chosidow, O.

Published
2024
Full Text
View/download PDF

5. Use of Systemic Medications for Treating Adult Atopic Dermatitis in France: Results of a Practice Survey

Author

Fougerousse AC, Jacobzone C, Mery-Bossard L, Reguiai Z, Droitcourt C, Taieb C, and Maccari F

Subjects
atopic dermatitis, cyclosporine, methotrexate, practice survey, Dermatology, RL1-803
Abstract

Anne-Claire Fougerousse,1 Caroline Jacobzone,2 Laure Mery-Bossard,3 Ziad Reguiai,4 Catherine Droitcourt,5 Charles Taieb,6 François Maccari7 On behalf of GEM ResoEczema Group1Dermatology Department, Hôpital d’Instruction des Armées Bégin, Saint Mandé, Val de Marne, France; 2Dermatology Department, Hôpital du Scroff, Groupe Hospitalier Bretagne Sud, Lorient, Morbihan, France; 3Dermatology Department, Centre Hospitalier Intercommunal Poissy Saint Germain en Laye, Saint-Germain-en-Laye, Yvelines, France; 4Dermatology Department, Polyclinique Courlancy, Reims, Marne, France; 5Dermatology Department, Centre Hospitalier Universitaire, Rennes, Ille et Vilaine, France; 6Emma Clinic, Fontenay-sous-Bois, Val de Marne, France; 7Private Practice, Saint-Maur-des-Fossés, Val de Marne, FranceCorrespondence: Anne-Claire FougerousseDermatology Department, Hôpital d’Instruction des Armées Bégin, Saint Mandé, Val de Marne, FranceEmail ac.fougerousse@gmail.comPurpose: Recent studies have illustrated that systemic medications are underused for treating adult atopic dermatitis (AD) and that dermatologists have concerns regarding the safety profile of cyclosporine in AD.Patients and Methods: We performed a national online practice survey between March and April 2020.Results: A total of 305 dermatologists responded, 57% with hospital-based activity and 43% with private practice. Overall, 46.9% prescribed cyclosporine for adult AD. Before initiating treatment, 56.9% did not perform evaluation scoring. Reasons for not prescribing cyclosporine were no eligible patients (24.7%), lack of information (52.6%), need for hospital prescription (31.2%), and lack of experience (79.2%). Fifty-four percent of the dermatologists prescribed methotrexate for adult AD. Before initiating treatment, 50.5% did not perform evaluation scoring. Reasons for not prescribing methotrexate were no eligible patients (46.7%), lack of information (39.3%), lack of experience (25.2%), and not approved for AD (47.4%). A total of 2.1% dermatologists prescribed other systemic treatments for adult AD, 9.8% prescribed corticosteroids and 56.4% prescribed dupilumab.Conclusion: Systemic treatments for AD are used by half of dermatologists, although cyclosporine and dupilumab must be initiated in hospitals in France. Methotrexate is more frequently used than cyclosporine, although it is not approved for this indication in France. A vast majority of dermatologists do not perform any evaluation scoring before initiating systemic treatment for adult AD.Keywords: atopic dermatitis, cyclosporine, methotrexate, practice survey

Published
2021

7. Atopic dermatitis and vitamin D supplementation: The end of the story?

Author

Droitcourt, C. and Arellano, J.

Subjects
*SUNSHINE, *VITAMIN D deficiency, *VITAMIN D, *DIETARY supplements, *CHILD patients
Abstract

A randomized controlled trial on the potential role of vitamin D in managing atopic dermatitis (AD) among children aged 2 to 17 years did not show a strong result in improving the severity of AD compared to a placebo. While there is evidence of a relationship between AD severity and vitamin D concentration, trials assessing vitamin D supplementation in AD pediatric populations have yielded contradictory results. It is important to determine whether the effect of vitamin D on AD is acute or long-term, as well as to consider the possibility that vitamin D deficiency may be a consequence of an altered skin barrier characteristic of AD. Further research is needed to fully understand the role of vitamin D in AD. [Extracted from the article]

Published
2024
Full Text
View/download PDF

8. Impact de la pandémie COVID-19 sur la prise en charge des patients adultes atteints de dermatite atopique modérée à sévère : analyse complémentaire de l’étude MOVE

Author

Lacour, J.P., primary, Fougerousse, A.C., additional, Becherel, P.A., additional, Droitcourt, C., additional, Dupuy, A., additional, Falissard, B., additional, Gackiere-Katsogiannou, M., additional, Aubert, N., additional, Thenie, C., additional, and Helman, N., additional

Published
2022
Full Text
View/download PDF

9. Efficacité et tolérance des inhibiteurs de Janus kinase dans le traitement de la dermatite atopique modérée à sévère de l’adulte réfractaire à d’autres systémiques: expérience en vraie vie

Author

Vanlerberghe, J., primary, Dezoteux, F., additional, Martin, C., additional, Jachiet, M., additional, Soria, A., additional, Tétart, F., additional, Modeste-Duval, A.B., additional, Bursztejn, A.C., additional, Misery, L., additional, Aubin, F., additional, Lasek, A., additional, Leleu, C., additional, Du Thanh, A., additional, Pasteur, J., additional, Pralong, P., additional, Nosbaum, A., additional, Droitcourt, C., additional, Viguier, M., additional, Tauber, M., additional, Seneschal, J., additional, Barbarot, S., additional, and Staumont-Sallé, D., additional

Published
2022
Full Text
View/download PDF

10. Hypersensibilité immédiate au dupilumab : une série de cas française

Author

Lemery, R., primary, Cariou, C., additional, Darrigade, A.S., additional, Rochefort-Morel, C., additional, Carvalho-Lallement, P., additional, Tedbirt, B., additional, Bergeron, S., additional, Sanchez-Pena, P., additional, Polard, E., additional, Picard, S., additional, Triquet, L., additional, Dupuy, A., additional, and Droitcourt, C., additional

Published
2022
Full Text
View/download PDF

11. Efficacité d’une intervention d’éducation thérapeutique courte par une infirmière dans la dermatite atopique de l’enfant. Étude randomisée contrôlée multicentrique

Author

Barbarot, S., primary, Aubert, H., additional, Vibet, M.A., additional, Leray, M., additional, Elan, F., additional, Meneron, L., additional, Stalder, J.F., additional, Mazereeuw-Hautier, J., additional, Phan, A., additional, Droitcourt, C., additional, Bursztejn, A.C., additional, Boralévi, F., additional, Chiaverini, C., additional, Raison Peyron, N., additional, Lasek, A., additional, Misery, L., additional, Abasq, C., additional, and Mallet, S., additional

Published
2022
Full Text
View/download PDF

12. VEGF, facteur tissulaire, marqueurs de la coagulation et de la fibrinolyse dans les malformations vasculaires à flux lent : étude prospective et impact du sirolimus

Author

Moineau, A.G., primary, Maruani, A., additional, Boccara, O., additional, Mazereeuw-Hautier, J., additional, Leducq, S., additional, Bessis, D., additional, Guibaud, L., additional, Vabres, P., additional, Mallet, S., additional, Barbarot, S., additional, Chiaverini, C., additional, Droitcourt, C., additional, Bursztejn, A.C., additional, Lengelle, C., additional, Woillard, J.B., additional, Herbreteau, D., additional, Le Touze, A., additional, Binet, A., additional, Morel, B., additional, Bourgoin, H., additional, Gissot, V., additional, Giraudeau, B., additional, Gruel, Y., additional, Tavernier, E., additional, and Rollin, J., additional

Published
2022
Full Text
View/download PDF

14. Clinical and haemodynamic risk factors associated with discrepancies in lower limb length with capillary malformations: data from the national paediatric French cohort CONAPE

Author

Samimi, M., Durieux‐Verde, M., Caille, A., Mazereeuw‐Hautier, J., Boccara, O., Martin, L., Chiaverini, C., Eschard, C., Beneton, N., Vabres, P., Balguerie, X., Plantin, P., Bessis, D., Barbarot, S., Dadban, A., Droitcourt, C., Leducq, S., Lorette, G., Morel, B., and Maruani, A.

Published
2018
Full Text
View/download PDF

17. Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicentre retrospective cohort in daily practice

Author

Lasek, A., Bellon, N., Mallet, S., Puzenat, E., Bursztejn, A.C., Abasq, C., Mazereeuw‐hautier, J, Chiaverini, C., Hubiche, T., Raison Peyron, N., Du Thanh, A., Barbarot, Sébastien, Aubert, H., Reguiai, Z., Droitcourt, C., Fievet, C., Bellissen, A., Bachelerie, M., Nosbaum, A., Leymarie, A., Armingaud, P., Masson Regnault, M., Mahé, E., Groupe Hospitalier de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Dermatologie et Allergologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Archet 2 [Nice] (CHU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Physiopathologie des Adaptations Nutritionnelles (PhAN), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Lille, CHU Marseille, CHU Clermont-Ferrand, Université de Lyon, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Régional d'Orléans (CHRO), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre Hospitalier Victor Dupouy, and None

Subjects
atopic dermatitis, Dermatology, Conjunctivitis, Severity of Illness Index, Dermatitis, Atopic, Immunoglobulin A, Cohort Studies, Infectious Diseases, Treatment Outcome, children, dupilumab, Humans, daily practice, Child, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Retrospective Studies
Abstract

International audience; Background: Dupilumab is the first biotherapy available for the treatment of moderate-to-severe childhood atopic dermatitis (AD).Objective: The aim of this study was to evaluate the effectiveness and safety of dupilumab in daily practice.Methods: Patients aged 6-11, who had received a first dose of dupilumab, were included in this multicentre retrospective cohort study. The primary endpoint was change in SCORAD after 3 months of treatment. Secondary endpoints were change in IGA score at 3 months, proportion of patients with SCORAD50 and SCORAD75, description of adverse events and proportion of children in our cohort who would be excluded from pivotal phase 3 clinical trial.Results: Eighty patients were included. After 3 months of treatment, there was a significant decrease in SCORAD (mean: 21.8 ± 13.8 vs 53.9 ± 18.5; P < 0.0001) and IGA (1.3 ± 0.8 vs 3.5 ± 0.7; P < 0.0001). Conjunctivitis was observed in 11.3% (n = 9/80); three patients experienced dupilumab facial redness (DFR); 17.5% (n = 14/80) reported injection site reactions; 6.3% (n = 5/80) discontinued treatment. 61.2% (n = 49/80) children were ineligible in the phase 3 trial.Limitations: There is no control group. Because it was a real life study based on information from patient medical records in a French multicentre cohort, we cannot rule out the presence of reporting bias generated by the use of patient reported characteristics and missing information.Conclusion: These real-life data confirm the efficacy and safety of dupilumab in children with moderate to severe AD extended to dyshidrosis and atopic prurigo, but it also revealed a lower frequency of DFR and conjunctivitis. However, administration in injectable form may be a barrier in this age group.

Published
2022

18. Association of psychiatric history with delay in the isotretinoin introduction among patients with severe acne. A French population-cohort study

Author

Laurent, C, Balusson, F, Droitcourt, C, Poizeau, F, Travers, D, Oger, E, Dupuy, A, Dupuy, Alain, Chard-Hutchinson, Xavier, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], This work was supported by a grant from the French Society of Dermatology (SFD, and Société Française de Dermatologie).

Subjects
[SDV] Life Sciences [q-bio], Infectious Diseases, [SDV]Life Sciences [q-bio], Dermatology, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract

International audience; No abstract available

Published
2022

27. Risk of systemic infections requiring hospitalization in children with atopic dermatitis:a Danish retrospective nationwide cohort study

Author

Droitcourt, C., Vittrup, I., Dupuy, A., Egeberg, A., Thyssen, J. P., Droitcourt, C., Vittrup, I., Dupuy, A., Egeberg, A., and Thyssen, J. P.

Abstract

Background: Infections can trigger worsening of atopic dermatitis (AD). Objectives: To examine whether hospital-managed paediatric AD is associated with increased risk of extracutaneous infections requiring hospitalization in childhood. Methods: A nationwide-based cohort study using Danish registries was done. Children aged < 18 years with a hospital diagnosis of AD and children without a hospital diagnosis of AD were sex- and age-matched at date of AD diagnosis. Study outcomes were extracutaneous infections that led to hospitalization. AD severity was defined according to prescriptions for treatments. Results: Of 19 415 children with AD [median follow-up 7·4 years; interquartile range (IQR) 3·3–13.3] and 194 150 without AD (median follow-up 7·7 years; IQR 3·6–13·5), 56% were boys and 50% were aged < 2 years. Children with AD had an increased rate of lower respiratory [LRTI; adjusted hazard ratio (aHR) 1·79, 95% confidence interval (CI) 1·65–1·94)], upper respiratory (URTI; aHR 1·59, 95% CI 1·34–1·88), urinary tract (UTI; aHR 1·34, 95% CI 1·16–1·54), musculoskeletal (MSSI; aHR 1·33, 95% CI 1·06–1·66) and gastrointestinal infections (GITIs; aHR 1·24, 95% CI 1·14–1·35) vs. children without AD. Associations did not clearly vary with AD severity. Absolute risk difference per 10 000 person-years was 26·4 (95% CI 23·0–29·8) for LRTIs, 3·1 (95% CI 1·6–4·7) for URTIs, 3·6 (95% CI 1·8–5·4) for UTIs, 0·9 (95% CI 0·2–2·0) for MSSIs and 8·7 (95% CI 5·7–11·7) for GITIs. Conclusions: Children with hospital-managed AD have an increased risk of systemic infections that lead to hospitalization; absolute risk is generally low.

Published
2021

28. Association between hospital-diagnosed atopic dermatitis and psychiatric disorders and medication use in childhood*

Author

Vittrup, I., Andersen, Y. M.F., Droitcourt, C., Skov, L., Egeberg, A., Fenton, M. C., Mina-Osorio, P., Boklage, S., Thyssen, J. P., Vittrup, I., Andersen, Y. M.F., Droitcourt, C., Skov, L., Egeberg, A., Fenton, M. C., Mina-Osorio, P., Boklage, S., and Thyssen, J. P.

Abstract

Background: While adult atopic dermatitis (AD) is associated with anxiety and depression, and paediatric AD is linked to attention deficit hyperactivity disorder (ADHD), the relationship between AD in childhood and other psychiatric disorders is largely unknown. Objectives: To determine the relationship between AD and diagnosis and treatment of psychiatric disorders in children. Methods: All Danish children born between 1 January 1995 and 31 December 2012 with a hospital diagnosis of AD (n = 14 283) were matched 1 : 10 with children without a hospital diagnosis of AD. Endpoints were psychotropic medication use, hospital diagnoses of depression, anxiety, ADHD, or self-harming behaviour, accidental/suicidal death, and consultation with a psychiatrist or psychologist. Results: Significant associations were observed between hospital-diagnosed AD and antidepressant [adjusted hazard ratio (aHR) 1·19, 95% confidence interval (CI) 1·04–1·36], anxiolytic (aHR 1·72, 95% CI 1·57–1·90), and centrally acting sympathomimetic (aHR 1·29, 95% CI 1·18–1·42) medication use. Consultation with a psychiatrist (aHR 1·33, 95% CI 1·16–1·52) or psychologist (aHR 1·25, 95% CI 1·11–1·41) was also associated with AD. No association with a hospital diagnosis of depression (aHR 0·58, 95% CI 0·21–1·56), anxiety (aHR 1·47, 95% CI 0·98–2·22) or self-harming behaviour (aHR 0·88, 95% CI 0·27–2·88) was observed, but a diagnosis of ADHD (aHR 1·91, 95% CI 1·56–2·32) was significantly associated with AD. The absolute risks were generally low. Conclusions: The increased risk of treatment, but not of a hospital diagnosis of psychiatric disorders in children with hospital-diagnosed AD, suggests that psychiatric issues in children with AD could be of a transient, reversible or mild–moderate nature.

Published
2021

32. Concordance of severity scores assessed on photographs in Hidradenitis suppurativa

Author

Prouteau, C, Dinulescu, M, oger, E, Pruvost-Balland, C, Buche, S, Cogrel, O, Delage, M, Maruani, A, Nicol, I, Sbidian, E, Villani, A P, Viguier, M, Chastagner, M, Grodner, C, Kaoutar, J, Laurent, C, Leducq, S, Dupuy, A, Droitcourt, C, CHU Pontchaillou [Rennes], Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Bordeaux [Bordeaux], Institut Pasteur [Paris] (IP), Centre Médical de l'Institut Pasteur (CMIP), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Marseille, Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Henri Mondor [Créteil], Centre d'Investigation Clinique Henri Mondor (CIC Henri Mondor), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire de Reims (CHU Reims), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Institut Pasteur [Paris], Centre Médical de l'Institut Pasteur, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, CHU Henri Mondor, and Jonchère, Laurent

Subjects
[SDV] Life Sciences [q-bio], Hidradenitis suppurativa, Standardized photographs, [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS, Photographic assessments
Abstract

International audience

Published
2020

33. DIAGNOSTIC PERFORMANCES OF HAND ULTRASOUND PARAMETERS AND THEIR IMPACT ON THE 2013 ACR/EULAR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS

Author

de Saint Riquier, M, Ballerie, A., Robin, F., Belhomme, Nicolas, Cazalets, C., Droitcourt, C., Perdriger, Aleth, Yelnik, C. M., Hachulla, Eric, Sobanski, Vincent, Jego, Patrick, Coiffier, Guillaume, Lescoat, A., CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), Stabilité génétique, cellules souches et radiations (SGCSR (U_1274 / UMR_E_008)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Paris (UP), Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université Paris Cité (UPCité), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

35. Durées de traitement et post-traitement des traitements systémiques dans une cohorte nationale française d’enfants ayant une dermatite atopique

Author

Chambrelan, E., primary, Barbarot, S., additional, Bekel, L., additional, Poizeau, F., additional, Mahé, E., additional, Puzenat, E., additional, Delaunay, J., additional, Mallet, S., additional, Bessis, D., additional, Maruani, A., additional, Miquel, J., additional, Raison-Peyron, N., additional, Darrieux, L., additional, Abasq, C., additional, Phan, A., additional, Aurélie, D.-T., additional, Kupfer, I., additional, Bonniaud, B., additional, Bouzille, G., additional, Law Ping Man, S., additional, Dupuy, A., additional, and Droitcourt, C., additional

Published
2020
Full Text
View/download PDF

39. Qualité de vie chez les enfants ayant une malformation capillaire de membre inférieur : données dynamiques sur 5 ans (cohorte nationale multicentrique CONAPE)

Author

Robert, J., primary, Marchand, A., additional, Mazereeuw-Hautier, J., additional, Boccara, O., additional, Martin, L., additional, Chiaverini, C., additional, Beneton, N., additional, Vabres, P., additional, Balguerie, X., additional, Plantin, P., additional, Bessis, D., additional, Barbarot, S., additional, Dadban, A., additional, Droitcourt, C., additional, Morel, B., additional, Leducq, S., additional, Samimi, M., additional, Caille, A., additional, and Maruani, A., additional

Published
2020
Full Text
View/download PDF

45. THU0352 DIAGNOSTIC PERFORMANCES OF HAND ULTRASOUND PARAMETERS AND THEIR IMPACT ON THE 2013 ACR/EULAR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS.

Author

De Saint Riquier, M., primary, Ballerie, A., additional, Robin, F., additional, Belhomme, N., additional, Cazalets, C., additional, Droitcourt, C., additional, Perdriger, A., additional, Yelnik, C. M., additional, Hachulla, E., additional, Sobanski, V., additional, Jégo, P., additional, Coiffier, G., additional, and Lescoat, A., additional

Published
2020
Full Text
View/download PDF

47. Identification du premier cas autochtone de xeroderma pigmentosum de type A en France : mutation homozygote XPA H244R contrastant avec un phénotype modéré sans atteinte neurologique

Author

Moisson-Franckhauser, C., primary, Law Ping Man, S., additional, Dubourg, C., additional, Carré, W., additional, Adamski, H., additional, Dinulescu, M., additional, Droitcourt, C., additional, Russo, D., additional, Menez, T., additional, Sarasin, A., additional, Dupuy, A., additional, and Boussemart, L., additional

Published
2019
Full Text
View/download PDF

49. Éfficacité et tolérance du dupilumab dans le prurigo nodulaire : étude rétrospective nationale multicentrique

Author

Calugareanu, A., primary, Jachiet, M., additional, Tauber, M., additional, Nosbaum, A., additional, Aubin, F., additional, Misery, L., additional, Droitcourt, C., additional, Barbarot, S., additional, Debarbieux, S., additional, Staumont-Sallé, D., additional, Sénéschal, J., additional, Bagot, M., additional, and Bouaziz, J.-D., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results